交易中 11-17 10:16:56 美东时间
+0.013
+1.56%
Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC) 50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group Median progression-free survival (mPFS) of 13.0 months,...
11-16 21:03
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.37) by 32.43 percent. This is a 79.84 percent increase over losses of $(1.24) per share from the same period last year.
08-07 05:58
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard...
07-09 20:05
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the
06-03 20:39
Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastomaTranslational data
05-14 20:08
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.69) by 62.32 percent. This is a 87.96 percent increase over losses of $(2.16) per share from the same
05-08 04:52
今日重点评级关注:Piper Sandler:维持Allogene疗法"超配"评级,目标价从7美元升至8美元;B. Riley证券:维持Oncology Institute"买入"评级,目标价从6美元升至8美元
03-16 18:19
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $6 price target.
03-13 20:01
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate
02-09 21:08
Gainers Clene (NASDAQ:CLNN) stock increased by 10.0% to $7.94 during Wednesday'...
2025-12-04 05:06